Palatin Technologies, Inc.
A biopharmaceutical company that develops medicines working on the body's melanocortin receptor system, Palatin Technologies is headquartered in Princeton, New Jersey. Its most visible product is Vyleesi, an FDA-approved injectable treatment for low sexual desire in premenopausal women, delivered through a self-administered autoinjector. Founded in 1986 by Carl Spana and John K.A. Prendergast, the company also develops treatments for obesity and rare metabolic disorders.
Granted 95.0K · Bought 106.0K · Sold 11.7K
Granted 936.2K · Bought 11.5K
Granted 814.7K · Bought 11.5K · Sold 10.6K
Granted 95.0K
Granted 95.0K
Granted 95.0K
Granted 97.0K · Bought 200 · Sold 400
Granted 130.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Deveer Robert K JrDirector · 12 transactions | -83% | 138.1Kas of May 2025 | 95.0K | 106.0K | 11.7K |
| Spana CarlPresident and CEO, Director · 59 transactions | -99.2% | 64.4K | 936.2K | 11.5K | — |
| Wills Stephen TExecutive VP and CFO/COO · 66 transactions | -99.2% | 63.4K | 814.7K | 11.5K | 10.6K |
| Hull Joseph StanleyDirector · 3 transactions | -94.6% | 42.3Kas of Jul 2024 | 95.0K | — | — |
| Morris ArleneDirector · 3 transactions | -94% | 41.6Kas of Jul 2024 | 95.0K | — | — |
| Manning Anthony M.Director · 3 transactions | -92.2% | 36.1Kas of Jul 2024 | 95.0K | — | — |
| Dunton Alan WDirector · 9 transactions | -98.2% | 14.1K | 97.0K | 200 | 400 |
| Prendergast John K ADirector · 5 transactions | -99% | 13.8K | 130.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +106.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.